Lubbeek, Belgium

Mathijs Baens


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2004-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Mathijs Baens

Introduction

Mathijs Baens is a notable inventor based in Lubbeek, Belgium. He has made significant contributions to the field of biotechnology, particularly in the molecular characterization of chromosome translocations and their implications in carcinogenesis. His work has led to advancements in understanding malignancies such as mucosa-associated lymphoid tissue (MALT) lymphomas.

Latest Patents

Mathijs Baens holds 2 patents that focus on the molecular characterization of chromosome translocation t(11;18)(q21;q21). His latest patents include methods for determining whether a tissue sample comprises a cell with a chromosome (11:18) translocation associated with malignancies. These inventions provide insights into a novel mechanism of transformation of primary cells, involving the expression of a fusion proteinaceous molecule that includes apoptosis inhibitor 2 (API2) fused to other proteinaceous molecules. Additionally, he has developed a novel nucleic acid sequence and a proteinaceous molecule termed 'MALT-lymphoma associated Translocation (MLT) protein.'

Career Highlights

Mathijs Baens is affiliated with the Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw, where he conducts his research and development activities. His work has been instrumental in advancing the understanding of genetic factors in cancer, particularly in relation to MALT lymphomas.

Collaborations

Throughout his career, Mathijs has collaborated with esteemed colleagues such as Judith Dierlamm and Peter Marijnen. These collaborations have enriched his research and contributed to the success of his innovative projects.

Conclusion

Mathijs Baens is a prominent figure in the field of biotechnology, with a focus on cancer research and molecular characterization. His patents and collaborative efforts continue to influence advancements in understanding and treating malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…